Inovio Pharmaceuticals' HIV DNA vaccine achieves strong T-Cell immune responses in Phase I human trial.

Inovio Pharmaceuticals Inc (Inovio) has announced that it has achieved high vaccine-induced response rates and strong magnitude of immune responses in its Phase I clinical study of Pennvax-B, a DNA vaccine for the prevention of HIV infection. Similar to recently reported results from a Phase I clinical study of Inovio's therapeutic DNA vaccine for cervical cancer, the response rates and magnitude of responses achieved in this study are significantly higher than those seen previously with other DNA vaccine trials. The interim immune response and safety data were presented at the Annual HIV Vaccine Trials Network Conference being held 15-17 Nov 2010, in Seattle, WA. This study, designated …